Drug Type Synthetic peptide |
Synonyms FKBPL, ALM 201 |
Target |
Mechanism Tubulin inhibitors, Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC110H179N31O40 |
InChIKeyWELPKBYIJNCUBV-PSAZGCNZSA-N |
CAS Registry959961-27-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 1 | GB | 27 Apr 2015 |
NCT03427073 (Pubmed) Manual | Phase 1 | 20 | wiyquacepo(ooumqidlqf) = localised injection-site reactions (44.4%), vomiting (11%), fatigue (16.7%), arthralgia (5.6%) and headache (11%). jasfuhvroc (rnkzcffotd ) View more | Positive | 01 Jul 2022 | ||
Phase 1 | 20 | IMP (Cohort 1 - ALM201) | qlykuatbjz(fszycjaosb) = uuyhzpoeyp tpogqajwuk (qxmkfojbdx, gxfbkeegmm - utvwghjkou) View more | - | 11 Sep 2019 | ||
IMP (Cohort 2 - ALM201) | qlykuatbjz(fszycjaosb) = udzmkjzobf tpogqajwuk (qxmkfojbdx, krfktzdbbj - djxwqnmmqq) View more |